Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B

NCT07137910 is registered in ClinicalTrials.gov with Ausper Biopharma Co., Ltd. as lead sponsor.

NCT NCT07137910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07137910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B
Lead sponsor
Ausper Biopharma Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
September 4, 2025
Completion date
June 1, 2027
Enrollment
200 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b